Last reviewed · How we verify
Clomid (clomifene)
At a glance
| Generic name | clomifene |
|---|---|
| Sponsor | Sanofi |
| Drug class | Estrogen Agonist/Antagonist |
| Target | 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1967 |
Approved indications
- Controlled ovarian stimulation
- Female infertility
- Induction of spermatogenesis
- Ovulation induction
Common side effects
- Ovarian Enlargement
- Vasomotor Flushes
- Abdominal-Pelvic Discomfort/Distention/Bloating
- Nausea and Vomiting
- Breast Discomfort
- Visual Symptoms
- Headache
- Abnormal Uterine Bleeding
- Fever
- Tinnitus
- Weakness
- Arrhythmia
Key clinical trials
- FRIEND: Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural CompounD in Green Tea (PHASE3)
- INTEnsity of ovariaN Stimulation and Embryo Quality (PHASE4)
- Sex Hormone Supplementation and Rotator Cuff Repair: A Preliminary Randomized Trial (PHASE2)
- Effect Clomiphene vs Clomiphene Along With Pioglitazone on Ovarian Stimulation Rate (PHASE4)
- The Effect Of Polycystic Ovarian Syndrome Treatment On Ocular Surface.
- The Effect of Therapy Combination in PCOS With Dlbs 3233 (EARLY_PHASE1)
- Vaginal Estradiol and Oral Guaifenesin in Clomiphene Ovulation Induction (NA)
- Ovarian Hyperstimulation and Fibrin Clot Properties. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clomid CI brief — competitive landscape report
- Clomid updates RSS · CI watch RSS
- Sanofi portfolio CI